GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Net Margin %

Peak Bio (Peak Bio) Net Margin % : 0.00% (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Peak Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Peak Bio's Net Income for the three months ended in Jun. 2023 was $-5.94 Mil. Peak Bio's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Peak Bio's net margin for the quarter that ended in Jun. 2023 was 0.00%.

The historical rank and industry rank for Peak Bio's Net Margin % or its related term are showing as below:

PKBO' s Net Margin % Range Over the Past 10 Years
Min: -4288.65   Med: -1861.72   Max: -1570.64
Current: -4288.65

PKBO's Net Margin % is ranked worse than
85.26% of 1031 companies
in the Biotechnology industry
Industry Median: -155.67 vs PKBO: -4288.65

Peak Bio Net Margin % Historical Data

The historical data trend for Peak Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peak Bio Net Margin % Chart

Peak Bio Annual Data
Trend Dec21 Dec22
Net Margin %
-1,570.64 -2,152.80

Peak Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Margin % Get a 7-Day Free Trial - - -2,169.90 - -

Competitive Comparison of Peak Bio's Net Margin %

For the Biotechnology subindustry, Peak Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Peak Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peak Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Peak Bio's Net Margin % falls into.


Peak Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Peak Bio's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-13.089/0.608
=-2,152.80 %

Peak Bio's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin=Net Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-5.944/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Peak Bio  (OTCPK:PKBO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Peak Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Peak Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Peak Bio (Peak Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Net Margin %
Comparable Companies
NBRVF BXRX AMPE ADTX DRMA SCPS RUBY INM GLMD RVLPQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
4900 Hopyard Road, Suite 100, Pleasanton, CA, USA, 94588
Website
https://www.peak-bio.com
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
Executives
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Michael R. Friedman director 245 E. 58TH STREET, APT #15B, NEW YORK NY 10022
Peter David Mccabe officer: General Counsel 584 CASTRO STREET, #882, SAN FRANCISCO CA 94114
Sbi Kis 2016-1 Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO GANGNAM, SEOUL M5 00000
2014 Kif-sbi It Investment Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
2019 Sbi Job Creation Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Investment Korea Co., Ltd. 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Healthcare Fund I 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Cross-border Advantage Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Bio Fund 1 Ikbc-sbi 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Gateway Fund 1 Global 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Satyajit Kumar Mitra officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Stephen J Lamond director, officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
David I. Rosenberg director C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019